Co-founder, Audax Biosciences
Appears in 1 story
Part of the founding shareholder group
A Melbourne drug developer founded by two researchers and funded largely from their own pockets has signed one of the biggest preclinical drug deals to come out of Australia. Japanese drugmaker Astellas now holds the exclusive option to license Audax Biosciences' lead cancer therapy worldwide, a package worth up to $1.34 billion before royalties.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
